cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1869Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMПрименение статинов при остром коронарном синдромеStatins in acute coronary syndromeДрапкинаО. М.DrapkinaO. M.

Заведующая отделением кардиологии клиники пропедевтики внутренних болезней им. В.Х.Василенко.

Тел.: 8-910-454-11-32

drapkina@dk.ruМосковская медицинская академия им. И.М. СеченоваI.M. Sechenov Moscow Medical Academy200920102009856973Copyright © Драпкина О.М., 20092009Драпкина О.М.Drapkina O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1869

Представлен обзор современной литературы, непосредственно касающейся снижения риска развития сердечно-сосудистых осложнений и смерти у пациентов, перенесших острый коронарный синдром (ОКС), при раннем назначении терапии статинами. Важное место в нем отведено обсуждению результа­тов последних мета-анализов и официальных рекомендаций. Наибольшую доказательную базу при ОКС имеет аторвастатин.

Ключевые слова: 

The article reviews the current evidence on reducing the risk of cardiovascular events and death in acute coronary syndrome patients (ACS) by early administration of statins. The results of the latest meta-analyses and official clinical recommendations are discussed. The statin with the strongest evidence on its benefits in ACS is atorvastatin.

статиныострый коронарный синдроматорвастатитнstatinsacute coronary syndromeatorvastatinReferencesBaigent C, Keech A, Keamey PM, et al. Efficacy and safety of cholesterol lowering treatment: respective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.Baigent C, Keech A, Keamey PM, et al. Efficacy and safety of cholesterol lowering treatment: respective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109(23) (Suppl 1): III39-43.Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109(23) (Suppl 1): III39-43.Link A, Ayadhi T. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006; 27: 2945¬55.Link A, Ayadhi T. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006; 27: 2945¬55.Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes JAMA 2001; 285: 1711-8.Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes JAMA 2001; 285: 1711-8.Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.de Lemos JA, Blazing MA, Wiviott SD, et al. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes Phase Z of the A to Z Trial. JAMA 2004; 292: 1307-16.de Lemos JA, Blazing MA, Wiviott SD, et al. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes Phase Z of the A to Z Trial. JAMA 2004; 292: 1307-16.Hulten E, Jackson JL, Douglas K, et al. The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome. Arch Intern Med 2006; 166: 1814-21.Hulten E, Jackson JL, Douglas K, et al. The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome. Arch Intern Med 2006; 166: 1814-21.Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 2007; 93: 914-21.Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. Heart 2007; 93: 914-21.Briel M, Schwartz GG, Thompson PL, et al. Effects of early treatment with statins on short term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006; 295: 2046-56.Briel M, Schwartz GG, Thompson PL, et al. Effects of early treatment with statins on short term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006; 295: 2046-56.Bassand J-P. Guidlines for diagnosis and treatment of non-ST- segment elevation ACS. Eur Heart J 2007; 28: 1598-660.Bassand J-P. Guidlines for diagnosis and treatment of non-ST- segment elevation ACS. Eur Heart J 2007; 28: 1598-660.Anderson JL. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. JACC 2007; 50: 1-157.Anderson JL. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. JACC 2007; 50: 1-157.Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 556-62.Bourcier T, Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 556-62.Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: 2356¬63.Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111: 2356¬63.Foussas SG, Zairis MN, Lyras AG, et al. Early prognostic usefulness of C-reactive protein added to the Thrombolysis In Myocardial Infarction risk score in acute coronary syndromes. Am J Cardiol 2005; 96: 533-7.Foussas SG, Zairis MN, Lyras AG, et al. Early prognostic usefulness of C-reactive protein added to the Thrombolysis In Myocardial Infarction risk score in acute coronary syndromes. Am J Cardiol 2005; 96: 533-7.Stone PH, Lloyd-Jones DM, Kinlay S, et al. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of of Myocardial Ischemia Study. Circulation 2005; 111: 1747-55.Stone PH, Lloyd-Jones DM, Kinlay S, et al. Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of of Myocardial Ischemia Study. Circulation 2005; 111: 1747-55.Muhlestein JB, Anderson JL, Horne BD, et al. Early effects of statins in patients with coronary artery disease and high C-reactive protein. Am J Cardiol 2004; 94: 1107-12.Muhlestein JB, Anderson JL, Horne BD, et al. Early effects of statins in patients with coronary artery disease and high C-reactive protein. Am J Cardiol 2004; 94: 1107-12.Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-80.Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-80.Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446-52.Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446-52.Choudhry NK, Levin R and Winkelmayer WC Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. Heart 2007; 93: 945-51.Choudhry NK, Levin R and Winkelmayer WC Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice. Heart 2007; 93: 945-51.http://clinicaltrials.gov:80/ct2/show/NCT00214630http://clinicaltrials.gov:80/ct2/show/NCT00214630Шевченко О.П., Шевченко А.О. Статины ингибиторы ГМГ- КоА-редуктазы. Москва, 2003.Шевченко О.П., Шевченко А.О. Статины ингибиторы ГМГ- КоА-редуктазы. Москва, 2003.Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992 Nov 7;340(8828):1111-5.Celermajer DS, Sorensen KE, Gooch VM et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992 Nov 7;340(8828):1111-5.Р.Г. Оганов, Д.М.Аронов, М.Г.Бубнова «Применение статинов — парадигма профилактики и лечения атеросклеротических заболеваний (фокус на аторвастатин)» Кардиоваск тер профил 2006, 6, 95-107.Р.Г. Оганов, Д.М.Аронов, М.Г.Бубнова «Применение статинов — парадигма профилактики и лечения атеросклеротических заболеваний (фокус на аторвастатин)» Кардиоваск тер профил 2006, 6, 95-107.

The authors declare that there are no conflicts of interest present.